{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-034239","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.007377+00:00","generated_at":"2026-06-04T21:39:50.684632+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Century Therapeutics reports FY2023 net loss $136.7M; cash $261.8M, runway into 2026","bullets":["Net loss $136.7M in 2023 vs $131.0M in 2022; R&D expenses $92.7M, down from $97.2M.","Cash, cash equivalents and investments $261.8M as of Dec 31, 2023; net cash used in ops $88.3M.","Collaboration revenue from BMS agreement $2.2M in 2023, down from $5.2M in 2022.","One-time impairment charge of $16.4M from consolidating facilities in Philadelphia and Seattle.","FY2024 GAAP operating expense guidance $135M-$145M; cash runway expected into 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-034239","json":"https://secwatch.observer/filing/0001104659-24-034239.json","markdown":"https://secwatch.observer/filing/0001104659-24-034239.md","text":"https://secwatch.observer/filing/0001104659-24-034239.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465924034239/0001104659-24-034239-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465924034239/tm248573d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T21:39:50.684632+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0cbc4ac22e3872d8c99141f8da90a980ce4fb151","claim":"Century Therapeutics, Inc. reported financial results for the full year ended December 31, 2023.","evidence_excerpt":"Century Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465924034239/0001104659-24-034239-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}